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OBJECTIVES This study was designed to evaluate the immediate and long-term clinical results of patients
undergoing endoluminal reconstruction in diffusely degenerated saphenous vein grafts
(SVGs) with elective implantation of one or more less-shortening Wallstents.
BACKGROUND The optimal treatment strategy for patients with diffusely degenerated SVGs is controversial.
Endoluminal reconstruction by stent implantation is one proposed strategy; however, there
are few data regarding long-term clinical outcome.
METHODS Between May 1995 and September 1998, 6,534 consecutive patients underwent angioplasty
in our institution, including 440 who were treated for SVG lesions. Of these, 126 (115 men,
11 women, median age 69.5 years, range: 33–86 years) with old SVGs (mean age: 13 6 5
years) diffusely degenerated stenosed or occluded (mean lesion length: 27 6 12 mm) were
treated electively with implantation of one or multiple (total 197) less-shortening Wallstents.
RESULTS Before discharge, 13 patients (10.3%) sustained at least one major cardiovascular event,
including 4 deaths (3.2%), 11 myocardial infarctions (MI) (8.7%), and 3 repeat revascular-
izations (target vessel 5 1, nontarget vessel 5 2, 2.4%). Surviving patients were followed for
22 6 11 months: 13 patients (11.1%) died, 11 (9.4%) sustained an MI, 37 underwent
angioplasty (31.6%), and 4 (3.4%) underwent bypass surgery. The estimated three-year
event-free survival rates (freedom from death, and freedom from death/MI/target vessel
revascularization) were (mean 6 SE) 81.1 6 7.8% and 43.2 6 18.5%, respectively.
CONCLUSIONS The long-term clinical outcome of patients undergoing endoluminal reconstruction in
diffusely degenerated SVG is relatively poor, mainly because of a high incidence of death or
MI and the frequent need for repeat angioplasty. It is unlikely that percutaneous intervention
alone will provide a satisfactory or definitive solution for these patients. (J Am Coll Cardiol
2000;36:387–94) © 2000 by the American College of Cardiology
Coronary artery bypass graft (CABG) surgery effectively
relieves angina in patients with obstructive coronary artery
disease and may prolong life in selected patients (1).
Recurrence of angina, however, occurs in 5% to 10% of
patients each year, mainly because of graft failure or a
combination of graft failure and progression of coronary
atherosclerosis (2,3). Beyond one year and particularly .3
years after surgery, atherosclerosis of vein grafts becomes
increasingly prevalent (4,5). Atherosclerosis may coexist
with intimal fibromuscular proliferation and, in patients
with acute ischemic syndromes, thrombus of varying ages.
Serial angiographic studies have revealed that 15% to 30% of
grafts are stenosed at one year after surgery and that nearly
50% are occluded at 10 years after surgery (4,6). The
increasing number of patients who have undergone bypass
surgery in which vein grafts were used has made vein bypass
graft disease a frequent therapeutic challenge. Repeat
CABG results in increased perioperative mortality (3%–7%)
and myocardial infarction (MI) incidence (3%–11%), and
less effective symptom relief compared with the initial
operation (7,8). Balloon angioplasty has been proposed as a
reasonable alternative but is associated with a higher rate of
acute complications in this situation than is observed during
interventions on native coronary arteries. Distal emboliza-
tion, which is particularly frequent (4%–13%), is associated
with a greater incidence of immediate and long-term
adverse events (9–11). Moreover, mid- and long-term
outcomes include high rates of restenosis (up to 46%) with
major adverse events (24%–43% at one year and 66%–74%
at five years) (9,12,13). Nonrandomized studies strongly
support the use of intracoronary stenting for focal lesions in
stenotic grafts (14–17), and there has been one randomized
clinical trial that compared stent implantation with percu-
taneous transluminal coronary angioplasty (PTCA) of
highly selected lesions that were short, focal and nonocclu-
sive (18). In that study, the incidence of non-Q wave MI
was only 2% in patients receiving stents, compared with 7%
in the PTCA group. There was a trend in favor of stent
placement for reduced angiographic restenosis. However, in
the case of diffusely degenerated saphenous vein grafts
(SVGs), the optimal treatment strategy, in particular the
strategy of performing “endoluminal reconstruction” by
stent implantation, has not been systematically studied.
The aim of this study was therefore to evaluate the
immediate and long-term clinical results of patients with
diffuse SVG lesions who underwent SVG reconstruction
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with elective implantation of one or multiple less-
shortening Wallstents.
METHODS
Patients
Between May 1995 and September 1998, out of 440
patients who underwent SVG angioplasty in our institution,
126 consecutive patients (29%) had diffusely degenerated
stenosed (i.e., isolated lesions of .20 mm in length, or
diffusely diseased segments with multiple/sequential steno-
ses) or occluded SVG. These patients underwent endolu-
minal reconstruction using less-shortening Wallstents.
These patients constituted 1.9% of the 6,534 patients who
underwent coronary angioplasty in our institution during
the same period. These 126 patients were considered to be
poor candidates for repeat surgery because of advanced age,
unfavorable coronary vessel anatomy, poor left ventricular
function or severe concomitant noncardiac disease and were
electively treated by implantation of one or multiple Wall-
stents.
Angioplasty procedure. Angioplasty was performed via
the transradial (61%), transfemoral (37%) or transbrachial
(2%) approach, using 6F (17%), 7F (48%) or 8F (35%)
guiding catheters. The lesion was carefully crossed using a
0.014 in. guidewire and predilated with an undersized
balloon inflated generally to 3–4 atm for #30 s in an
attempt to minimize the risk of distal embolization. In all of
the study patients, Wallstents were used for SVG recon-
struction. This stent is a self-expanding device whose
deployment does not require high-pressure balloon infla-
tion, and which is available in a large range of lengths (up to
50 mm) and sizes (up to 6 mm). Stents were generally
chosen with a diameter 1.5 mm larger than the reference
diameter of the graft and with a length 15 mm longer than
the stenotic lesion. Intravascular ultrasound was not used
during any implantation procedures. The arterial access
sheaths were removed immediately after transradial proce-
dures and immediately or 4 to 6 h after transfemoral
procedure. Hemostasis was achieved by using the Perclose
device or mechanical compression (Femostop device) for up
to 2 h in patients treated via the transfemoral approach, and
by radial compression with a tourniquet for 1 h in patients
treated via the transradial approach.
Angiographic assessment. After intracoronary injection of
isosorbide dinitrate (3 mg) and lisindomine (1 mg), refer-
ence vessel diameter, minimum lumen diameter and lesion
length were calculated using an online quantitative coronary
analysis (DCI Philips system, The Netherlands). The fol-
lowing definitions were used for angiographic assessment:
diffuse degenerated graft disease 5 isolated lesions of
.20 mm in length, or diffusely diseased segments with
multiple/sequential stenoses; thrombus 5 circumscribed
intraluminal filling defect; angiographic success 5 smooth
lumen surface at the stent site with a final diameter stenosis
,10%; distal embolization 5 new appearance of filling
defects and/or abrupt cutoff of the vessel distal to the target
lesion and/or decreased antegrade flow in the distal vessel
previously patent, in the absence of an occlusion of the
target lesion; no reflow 5 poor antegrade flow (Thrombol-
ysis in MI [TIMI] grade #1) not explained by dissection or
high-grade residual stenosis at or adjacent to the target
lesion; abrupt closure 5 poor antegrade flow (TIMI grade
#1) due to acute occlusion of the target lesion.
Anticoagulant and antiplatelet regimen. All patients ex-
cept those presenting with acute MI were pretreated for at
least three days with aspirin (100–250 mg o.d.), ticlopidine
(250 mg b.d.) and enoxaparin (100 UI/kg b.d). An intrave-
nous bolus of heparin (70 UI/kg) was administered after
arterial sheath placement and additional heparin boluses
were repeated as necessary to maintain the activated clotting
time between 250 and 300 s. Thirty-seven (29.4%) patients
were treated with abciximab therapy, including a
0.25 mg/kg bolus initiated immediately before the proce-
dure followed by a 0.125 mg/kg/min infusion for 12 h. After
the procedure, all patients received 1 month ticlopidine (250
o.d. or b.d.) and long-term aspirin (100–250 mg o.d.). In
the beginning of our experience, 14 patients with intracoro-
nary thrombus were treated by enoxaparin for one to three
days after the procedure, together with aspirin and ticlopi-
dine. After the occurrence of a major intracranial hemor-
rhage in one patient treated after the procedure by enox-
aparin, we decided to discontinue the use of anticoagulation
after PTCA.
Data collection and follow-up. Clinical, angiographic and
procedural data as well as postprocedural complications
were prospectively entered into a computerized database
(AS400, Showcase Strategy). Clinical follow-up was per-
formed by an experienced physician who made telephone
contact with the patients or their referring physicians.
Information obtained included occurrence of recurrent an-
gina, MI (defined by the development of new Q waves or
increase in the serum cardiac enzymes to more than twice
the upper limit of normal), subsequent cardiac catheteriza-
tions, need for repeat PTCA or additional CABG of target
and nontarget vessel and death (cardiac and noncardiac).
Follow-up data were entered into the computerized data-
base. Initial and follow-up data of the studied patients were
retrospectively analyzed.
Statistical analysis. Categorical variables were expressed as
percent frequencies and continuous variables as mean
value 6 SD, or median (range and interquartile range).
Chi-square analysis or the Fisher exact test were used for
comparison between groups for categorical variables where
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft
MI 5 myocardial infarction
PTCA 5 percutaneous transluminal coronary angioplasty
SVG 5 saphenous vein graft
TIMI 5 Thrombolysis in Myocardial Infarction
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appropriate, and the Student t test was used for normally
distributed continuous variables. Predictors of cardiovascu-
lar events were determined by univariate analysis. A multi-
variate model of predictors of adverse outcome did not have
sufficient power to discriminate the events, and the data are
not presented. Out-of-hospital event-free survival analysis
was performed using the Kaplan-Meier method, and four
hierarchical event-free survival curves were generated: (1)
freedom from death; (2) freedom from death and nonfatal
MI; (3) freedom from death, nonfatal MI and repeat target
vessel revascularization; (4) freedom from death, nonfatal
MI and any repeat coronary vessel revascularization. A p
value ,0.05 was considered significant.
RESULTS
The baseline clinical characteristics of the 126 study patients
are shown in Table 1. There was a high incidence of
unstable angina (48.4%). A previous MI (.1 month) had
occurred in 51 (40.4 %) patients. Recent MI (,30 days)
occurred in 20 patients, of whom 10 were admitted in our
institution within 72 h. Four of these with acute MI
(,12 h) were treated by immediate PTCA. These patients
were given aspirin and heparin on admission but did not
receive our usual prolonged antiplatelet pretreatment. The
remaining six patients underwent diagnostic catheterization
and then received pre-treatment for at least three days with
aspirin, ticlopidine and enoxaparin before undergoing
PTCA. Previous PTCA had been performed in 54 patients
(42.8%), of whom 31 (24.6%) had restenosis of the target
vessel. The average vein graft age was 12.8 years (range
1–23.7 years), with 110 (87.3%) . 4 years old.
Angiographic findings. Single and multivessel coronary
artery disease was present in 3.9% and 96.1% of the patients,
respectively. The mean left ventricular ejection fraction was
55 6 12% (range 20%–80%). The treated SVGs were
anastamosed to the left anterior descending artery and/or
diagonal branch (36.2%), left circumflex artery and/or mar-
ginal branch (39.8%) and right coronary artery (24%),
respectively. The PTCA was performed for de novo lesion
in 95 patients and for restenosis in 31 patients (Table 1).
There were 138 treated SVGs (1.1 grafts/patient), with
stenoses located proximally in 28.6%, in the graft body in
93.6% and distally in 15.9%. Mean lesion length was 27.1 6
12.1 mm (range 8–80 mm) and preprocedural percentage
stenosis was 79.2 6 10.4%. Angiographic evidence of
significant thrombus at the target site was found in 48
patients (38%). Successful implantation of a total of 197
Wallstents was achieved, representing 1.43 Wallstents per
graft and 1.56 Wallstents per patient, with a mean final
diameter of 3.9 6 0.5 mm. Length of the Wallstent per
graft was 44.5 6 16.7 mm (range 23–126 mm) (Table 2).
Seventeen additional stents were implanted in the grafts in
addition to the Wallstents, including five AVE stents, three
Nir stents, three Wiktor stents, two Palmaz-Schatz stents,
two Be-stents, one Enforcer stent, and one GFX stent.
Total stented length per graft, including the 17 additional
stents, was 46.4 6 17.4 mm (range 23–126 mm). No-reflow
was observed in one patient and abrupt closure in none.
Distal embolizations occurred in nine patients (7.1%) of
whom three had received abciximab during the procedure.
Five of these cases occurred after the predilation with an
undersized balloon inflation and four after Wallstent de-
Table 1. Baseline Clinical and Angiographic Characteristics of
126 Study Patients
Median age (yr) 69.5 6 6.3
Range 33–86
Male gender 115 (91.2)
Risk factors
History of smoking 67 (53.2)
Hypercholesterolemia 67 (53.2)
Hypertension 45 (35.7)
Diabetes 20 (15.8)
Previous MI (.1 month) 51 (40.4)
Recent MI (,1 month) 20 (15.8)
Stable angina 24 (19.0)
Unstable angina 61 (48.4)
Previous PTCA 54 (42.8)
Vessel disease
1 5 (3.9)
2 11 (8.7)
3 110 (87.3)
SVG age (yr) 12.8 (1–23.7)
SVG location
LAD 50 (39.6)
LCx/obtuse marginal 55 (43.6)
RCA 33 (26.1)
LV ejection fraction (%) 55.5 6 12
Angiographic indication
Primary lesion 95 (75.3)
Restenosis 31 (24.6)
Data presented are mean 6 SD or number (%) of patients.
MI 5 myocardial infarction; PTCA 5 percutaneous transluminal coronary
angioplasty; SVG 5 saphenous vein graft; LAD 5 left anterior descending coronary
artery; LCx 5 left circumflex artery; RCA 5 right coronary artery; LV 5 left
ventricular.
Table 2. Wallstent Implantation and Quantitative and
Qualitative Angiographic Data
Stent data
Total number of Wallstents 197
Number of Wallstent/patients 1.56
Number of Wallstent/graft 1.43
Wallstent length/graft (mm) 44.5 6 16.7
Quantitative angiographic data
Reference diameter (mm)
Before stenting 3.8 6 0.7
After stenting 3.9 6 0.5
Minimal lumen diameter (mm)
Before stenting 1.0 6 0.6
After stenting 3.9 6 0.5
Diameter stenosis (%)
Before stenting 79.2 6 10.4
After stenting 2.9 6 4.3
Lesion length (mm)
Before stenting 27.1 6 12.1
Qualitative angiographic data
Chronically occluded grafts 15 (11.9)
Presence of thrombus 48 (38.0)
Data presented are mean 6 SD or number (%) of patients.
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ployment. Among the nine patients with distal emboliza-
tion, eight had ECG changes during the invasive procedure
and four developed chest pain. Other coronary lesions were
simultaneously treated in 38 patients (30.1%), located in a
native coronary artery in 27 patients, in other SVG in 10
patients and in an internal mammary artery graft in 2
patients.
In-hospital outcome. In-hospital complications are re-
ported in Table 3. Four patients (3.1%) died, two from
cardiac causes. The first developed cardiogenic shock fol-
lowing distal embolization. The second died from ventric-
ular fibrillation complicating anterior MI three days after
the procedure. Noncardiac deaths included two strokes,
both confirmed by computed tomographic scanning: one
intracranial hemorrhage occurring three days after the
procedure and one subclavian dissection caused by a trans-
radial guiding catheter complicated by carotid hematoma.
One of these patients had received abciximab therapy
during PTCA, and both were treated with enoxaparin after
the procedure.
Nine other patients (7.1%), including three who had
received abciximab therapy, developed MI that was fre-
quently associated with distal embolization. Among these
patients, one was electively treated with CABG three days
after the procedure and one who developed recurrent angina
2 h after stent implantation underwent PTCA of the left
main coronary and the marginal branch. As a result, the
overall clinical success rate was 89.7%.
In addition, one patient had transient ischemic stroke
without sequelae. Eight patients (6.3%) had vascular access
site complications, of which two received blood transfusion
and two required surgical repair. One patient who had
received abciximab therapy during PTCA had major throm-
bocytopenia (800 platelets/mm3), necessitating blood trans-
fusion 24 h after the procedure, and one patient developed
gastrointestinal bleeding. One hundred twenty-two patients
were discharged alive (96.8%). The median hospital stay for
the total cohort was 5.0 days (range 2–16 days, interquartile
range 4–8 days).
Clinical events after hospital discharge. Follow-up (mean
duration 21.6 6 11.3 months) was obtained in 117 (95.9%)
of the 122 discharged alive patients. After the PTCA, 57
patients had no further angina and 60 patients developed
angina during follow-up, of which 60% had at least one
episode of unstable angina. Table 3 lists the occurrence of
major events after hospital discharge. There were 13 deaths
(11%), 9 of which were cardiac and 4 noncardiac. Univariate
analysis indicated that increasing age of the patients (68.0
years 6 8.1 vs. 74.9 years 6 5.3, p 5 0.001) and lower
ejection fraction (56.9% 6 13.9% vs. 47.0% 6 17.9%, p 5
0.02) were predictors of deaths during follow-up. Six
patients (5.1%) sustained a nonfatal MI. Four patients
(3.4%) underwent repeat bypass surgery. Two of these four
patients had unstable angina and two had stable angina
before surgery. The indication for repeat surgery was severe
and diffuse restenosis in two cases at 2 and 42 months, and
total occlusion of the target vessel associated with progres-
sive coronary disease in nontarget vessels at 6 months
follow-up. Diabetes mellitus, hypercholesterolemia, vein
graft age, previous coronary angioplasty at the stent site,
abciximab treatment during the procedure, lesion length,
Wallstent length per graft, and final percent diameter
stenosis were not predictive of the composite of death, MI
and target vessel revascularization (Table 4).
Restenosis. Follow-up angiograms were performed in 58
patients (48%) at a mean follow-up duration of 8.8 6 6.2
months (range 1–43 months). The indications for angiog-
raphy were unstable angina in 27 patients, stable angina
and/or positive exercise test in 26 and MI in 5. The
follow-up angiograms showed 34 restenoses, of which 14
were totally occluded, giving a 58.6% “angiographic” resten-
osis rate in this group of symptomatic patients. Initial lesion
length was found to be associated with further vessel
occlusion in univariate analysis (33.0 6 4.9 vs. 23.8 6
1.8 mm: p 5 0.03). Vein graft age, diabetes mellitus,
previous coronary angioplasty at the stent site, reference
vessel diameter, post-stent minimal luminal diameter and
final percent diameter stenosis were not associated with
restenosis. Furthermore, 27 patients had stenosis of a
Table 3. Major Cardiovascular Events During Hospital Stay and After Discharge
In-hospital (n 5 126) After Discharge (n 5 117)* Total (n 5 121)
Total Ranking Total Ranking Total Ranking
Event
Death 4 (3%) 4 (3%) 13 (11%) 13 (11%) 17 (14%) 17 (14%)
MI 11 (9%) 9 (7%) 11 (9%) 6 (5%) 21 (17%) 14 (11%)
CABG (target lesion) 0 0 3 (2%) 3 (3%) 3 (2%) 3 (2%)
Re-PTCA (target lesion) 1 (1%) 0 24 (20%) 22 (19%) 25 (21%) 17 (14%)
Nontarget vessel revascularization
CABG 1 (1%) 0 1 (1%) 1 (1%) 2 (2%) 1 (1%)
Re-PTCA 1 (1%) 0 23 (19%) 15 (13%) 23 (19%) 15 (12%)
Total 18 (14%) 13 (10%) 75 (64%) 60 (51%) 91 (75%) 67 (55%)
*Five patients lost to follow-up. Data presented are number (%) of patients.
Ranking 5 frequency of events in descending order: death (worst outcome), followed in order of rank by myocardial infarction (MI), bypass surgery (CABG) of target lesion,
repeat intervention (Re-PTCA) of target lesion, bypass surgery (CABG) of nontarget lesion, repeat intervention (Re-PTCA) of nontarget lesion. Total 5 total count of all events
(nonmutually exclusive analysis).
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nontarget vessel: 17 in native coronary arteries and 10 in
nontarget SVG.
Repeat PTCA was performed in 38 patients at a median
interval of 7.6 months (range 1–32 months): 15 underwent
repeat target vessel revascularization, 13 underwent nontar-
get vessel revascularization and 10 underwent both target
and nontarget repeat PTCA. The indication to perform
repeat target lesion angioplasty was restenosis in or adjacent
to the stented graft segment in all cases, with total occlusion
in three cases. Nontarget vessel revascularization was due to
progressive coronary disease in nontarget vessels.
Survival and event-free survival. Survival at six months
and at three years were 94.2 6 2.2% and 81.1 6 7.8%,
respectively. Freedom from death, MI and target vessel
revascularization at six months and at three years, including
events ccurring during the initial hospitalization, was
Figure 1. Survival and event-free survival curves (Kaplan-Meier) of patients who underwent Wallstent implantation in a vein graft. MI 5 myocardial
infarction; TVR 5 target vessel revascularization; REVASC 5 revascularization.
Table 4. Clinical and Angiographic Characteristics of Patients With and Without the
Composite of Death, MI, or TVR
Variables
No Death/MI/
TVR Death/MI/TVR
p-Value
Univariate
Patients, n (%) 75/126 (59) 51/126 (41)
Age, years 67.8 6 8.7 70.4 6 7.2 0.08
Diabetes, n (%) 13/75 (17) 7/51 (14) 0.97
Hypercholesterolemia, n (%) 43/75 (57) 24/51 (47) 0.34
Recent MI (,1 month), n (%) 10/75 (13) 10/51 (20) 0.36
MI within 72 h before admission, n (%) 7/75 (9) 3/51 (6) 0.71
Unstable angina at admission, n (%) 32/75 (43) 29/51 (57) 0.17
Previous target vessel PTCA, n (%) 15/75 (20) 16/51 (31) 0.21
LV ejection fraction, % 56.9 6 13.3 54.7 6 16.6 0.61
SVG age, years 11.8 6 4.9 12.3 6 5.0 0.59
Treatment by abciximab, n (%) 19/75 (25) 18/51 (35) 0.31
Chronically occluded grafts, n (%) 8/75 (11) 7/51 (14) 0.81
Presence of coronary thrombus, n (%) 26/75 (35) 22/51 (43) 0.30
Lesion length, mm 27.2 6 13.3 27.0 6 17.4 0.92
Stent length/graft, mm 47.9 6 23.6 44.0 6 21.6 0.36
Wallstent length/graft, mm 46.0 6 22.6 42.4 6 21.2 0.37
Diameter stenosis before stenting, % 79.3 6 13.6 78.9 6 12.6 0.86
Diameter stenosis after stenting, % 3.2 6 7.0 2.4 6 0.5 0.55
Data presented are mean value 6 SD or number (%) of patients.
MI 5 myocardial infarction; TVR 5 target vessel revascularization; PTCA 5 percutaneous transluminal coronary
angioplasty; LV 5 left ventricular; SVG 5 saphenous vein graft.
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79.1 6 4.2% and 43.2 6 18.5%, respectively (Fig. 1). At
three years, only 36.2 6 17.0% of the patients were free
from death, MI, and any coronary revascularization.
DISCUSSION
Management of recurrent ischemia in patients who have
diffuse SVG lesions remains challenging and controversial
(19). This report documents a single center’s experience of
126 consecutive patients undergoing endoluminal recon-
struction of diffusely degenerated stenosed or occluded SVG
with less-shortening Wallstents. The most important find-
ings of our study are that despite initially successful results,
this practice was associated with a poor short-term and
long-term clinical outcome. Increasing operator expertise
and technical improvements in angioplasty equipment and
adjunctive medical therapy such as aspirin, ticlopidine,
heparin and abciximab have made it possible to perform
endoluminal reconstruction of diffusely degenerated SVGs
with a high technical success rate. Nevertheless, the long-
term results remain disappointing, first because of frequent
in-hospital complications and second because of graft re-
stenosis and/or progression of coronary atherosclerosis. In
all, 55% of patients in this study died, had an MI, or
required repeat revascularization during the mean 21.6-
months follow-up. Nevertheless, these results should be
seen in the context that the majority of these patients were
considered to be poor surgical candidates and at increased
risk for a second or third bypass operation because of
advanced age, unfavorable coronary vessel anatomy, poor
left ventricular function or general status.
Immediate Results
In our study, successful stent implantation was achieved in
all cases, as in previous studies reporting the use of Walls-
tents for treating SVG disease (20–24). The frequency of
in-hospital major events including death, MI, emergency
CABG or PTCA was relatively high (see Table 3) com-
pared with previous reports (0 to 11%) (15–18,20,23–28).
Distal embolization, observed in nine patients (7.1%),
occurred relatively frequently. As serum level measurements
of creatine kinase with MB fraction were not systematically
performed after the procedure, some non-Q wave MIs were
undoubtedly missed, resulting in an underestimate of the
cardiac complication rate. In a pooled analysis of 16 studies
(9), SVG balloon angioplasty was associated with a high
procedural success rate (about 90%) and a lower incidence of
death (,1%), MI (,3%), distal embolization (,3%) and
emergency CABG (,2%). However, these findings are
primarily concerned with the treatment of focal lesions, with
70% to 80% of the patients having a discrete lesion ,10 to
13 mm long. In addition, in our study, patients were
generally older, with advanced graft age, and our results may
well be influenced accordingly. It has been well established
that procedural results depend in part on the “diffuseness” of
SVG disease, the age of the graft, and presence of thrombus
(9).
Implantation of Palmaz-Schatz stents has been shown to
decrease the incidence of adverse events (20%–30% at one
year) and restenosis (13%–37%) compared with balloon
angioplasty (15,16). However, the majority of studies of
stent implantation have primarily concerned the treatment
of focal lesions. Moreover, the results of the sole random-
ized trial published are disappointing, with a 37% restenosis
rate in the stent group (18).
Our treatment strategy was initially based on an angio-
scopic study that found evidence of thrombus in 71% of
SVGs treated by angioplasty (29), and the proved beneficial
effect of the use of ticlopidine and aspirin in reducing
platelet aggregation and coagulation activation during an-
gioplasty procedures (30). Furthermore, one-third of our
patients received abciximab therapy according to the as-
sumption that patients with complex or thrombus-
associated morphologies might derive additional benefit
from platelet IIb/IIIa inhibition. Nevertheless, in our study
we found no reduction of major coronary events in patients
treated by abciximab (Table 4). This result is consistent with
data from Ellis et al. (31) concerning the absence of
beneficial effect of abciximab compared with placebo for
patients with degenerated SVG. One might postulate that
the stimulus for thrombosis in this situation was more
dependent on the coagulation cascade than on platelet
activation and that pretreatment with enoxaparin, aspirin
and ticlopidine may be more likely to be of benefit than
acute administration of IIb/IIIa inhibitors. Moreover, we
used Wallstents, whose self-expanding property allows
avoidance of balloon inflation for implantation and whose
elastic wire mesh design would theoretically aid the entrap-
ment of macroscopic friable SVG material.
Major bleeding and vascular complications resulted in
two deaths in our study. This may have resulted in part from
the aggressive antiplatelet and anticoagulant regimen that
was used. However, such complications were also frequent
in the other series despite different antiplatelet and antico-
agulant treatments. Bleeding/vascular complications have
been observed in up to 33% of patients and have been
frequently related to in-hospital mortality (15–18,20–
26,28). De Scheerder et al. (23), who performed intragraft
administration of thrombolytic agents during the procedure,
observed bleeding complications in 33% of patients, includ-
ing two fatal hemorrhagic strokes. On the other hand, there
was no clinically apparent subacute stent thrombosis in our
study, contrasting with an incidence of 1% to 10% reported
in the literature (15–18,20–26,28).
Long-Term Results
During the mean follow-up period of 21.6 6 11.3 months,
one-third of our patients experienced major events (death or
MI) and more than one-third underwent repeat revascular-
ization. These results are quite similar to those previously
reported after SVG stent implantation, even though our
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series included only patients with diffuse lesions. One-year
event-free survival has been reported at from 46% to 80%
(15–17,20,21,26–28). Importantly, the most disappointing
results were observed in the series of De Jaegere et al. (20),
in which 52% of stent implantations (mainly Wallstents)
was performed for long SVG lesions. In that study, 23% of
patients developed MI and 50% underwent repeat revascu-
larization at a median of six months after the procedure.
Adverse outcome after SVG stenting has been thought to be
partly related to restenosis. Angiographic follow-up revealed
a restenosis rate of 17% to 37% in the series utilizing
Palmaz-Schatz stents (15–18,25,26,28) and 20% to 54% in
those using Wallstents (20–24). In our study, only symp-
tomatic patients underwent repeat angiography, and the
59% angiographic restenosis rate was therefore likely over-
estimated.
Our choice to perform elective SVG “reconstruction”
with long stents in order to cover segments of the grafts that
were not severely narrowed was based on studies that
reported a 27% to 34% rate of revascularization procedures
in relation to SVG disease progression (23,25). Indeed, Ellis
et al. (32) have found that 45% of recurrent ischemic events
after SVG interventions result from initially untreated
40%–50% stenosed sites, as compared with the 19% of
events related to initially treated 40%–50% stenosed seg-
ments. However, our strategy to perform SVG reconstruc-
tion with long stents might well have been partly responsible
for the high incidence of restenosis we observed.
CONCLUSIONS
The present study clearly demonstrates that reconstruction
of diffusely degenerated SVGs by implantation of self-
expandable less-shortening Wallstents with preventive an-
tiplatelet and anticoagulant treatment can be achieved with
high deployment and procedural success, but was associated
with a significant incidence of early complications. Long-
term clinical outcome was marked by a relatively high
cardiovascular morbidity and mortality. However, the clin-
ical status of our population, at high risk for repeat CABG,
should be taken into account when interpreting these
results. Further studies, including the use of new antiplatelet
and anticoagulant therapies and new device technology (33),
will be needed to clarify the optimal strategies for treating
these difficult patients.
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